Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:JUNO
CUSIPN/A
Phone+1-206-5821600
Debt
Debt-to-Equity Ratio0.01
Current Ratio3.61
Quick Ratio4.77
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$111.87 million
Price / Sales90.26
Cash FlowN/A
Price / CashN/A
Book Value$10.18 per share
Price / Book8.54
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-245,580,000.00
Net Margins-390.66%
Return on Equity-39.24%
Return on Assets-29.31%
Miscellaneous
Employees553
Outstanding Shares116,110,000
Market Cap$9.93 billion
Juno Therapeutics (NASDAQ:JUNO) Frequently Asked Questions
What is Juno Therapeutics' stock symbol?
Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."
How were Juno Therapeutics' earnings last quarter?
Juno Therapeutics Inc (NASDAQ:JUNO) posted its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.80) by $0.07. The biopharmaceutical company had revenue of $44.80 million for the quarter, compared to analysts' expectations of $18.12 million. Juno Therapeutics had a negative net margin of 390.66% and a negative return on equity of 39.24%. The company's quarterly revenue was up 115.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.57) EPS. View Juno Therapeutics' Earnings History.
What price target have analysts set for JUNO?
15 equities research analysts have issued twelve-month price objectives for Juno Therapeutics' shares. Their forecasts range from $43.00 to $87.00. On average, they anticipate Juno Therapeutics' share price to reach $61.6364 in the next twelve months. This suggests that the stock has a possible downside of 29.1%. View Analyst Price Targets for Juno Therapeutics.
What is the consensus analysts' recommendation for Juno Therapeutics?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Juno Therapeutics in the last year. There are currently 13 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Juno Therapeutics.
What are Wall Street analysts saying about Juno Therapeutics stock?
Here are some recent quotes from research analysts about Juno Therapeutics stock:
- 1. According to Zacks Investment Research, "Juno remains on track with its pipeline and continues to pursue acquisitions and licensing agreements. The company’s deal with Celgene for global development and commercialization of immunotherapies is encouraging. Moreover, the company’s targeted, cancer immunotherapy is a highly lucrative area as these therapies have the potential to change the treatment paradigm for cancer. Shares of the company have also outperformed the industry in the last one year. However, the company suffered a huge setback with discontinuation of the development of cancer candidate, JCAR015, due to the toxicity witnessed in a phase II ROCKET study. Also, increased competition in the immunotherapy space is a matter of concern for the company. Juno’s pipeline candidates are still a few steps away from approval and hence, any setback would weigh heavily on the stock." (2/21/2018)
- 2. Maxim Group analysts commented, "The American Society of Hematology (ASH) is now over, and while we saw bluebird’s (BLUE – $190.95 – Hold) valuation rise to over $9B on strong data in CAR-T and gene therapy, Juno’s valuation has seen a retracement from its pre- ASH peak of $7B, to $5B on what is incremental data for lead CAR candidate JCAR017." (12/13/2017)
Who are Juno Therapeutics' key executives?
Juno Therapeutics' management team includes the folowing people:
- Howard H. Pien, Independent Chairman of the Board (Age 59)
- Hans Edgar Bishop, President, Chief Executive Officer, Director (Age 53)
- Sunil Agarwal M.D., President of Research & Development (Age 47)
- Steven D. Harr M.D., Chief Financial Officer, Head of Corporate Development (Age 46)
- Hyam I. Levitsky M.D, Executive vice president - Research, chief scientific officer (Age 54)
- Robert W. Azelby, Executive Vice President, Chief Commercial Officer (Age 49)
- Ann Lee Ph.D., Executive Vice President - Technical Operations
- Patrick Y. Yang, Executive Vice President (Age 69)
- Cynthia Elkins, Chief Information Officer
- Bernard J. Cassidy, General Counsel, Secretary (Age 62)
When did Juno Therapeutics IPO?
(JUNO) raised $153 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 9,300,000 shares at $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager.
Has Juno Therapeutics been receiving favorable news coverage?
News coverage about JUNO stock has been trending somewhat positive this week, according to Accern. Accern ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Juno Therapeutics earned a coverage optimism score of 0.18 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Juno Therapeutics.
How do I buy shares of Juno Therapeutics?
Shares of JUNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Juno Therapeutics' stock price today?
One share of JUNO stock can currently be purchased for approximately $86.96.
How big of a company is Juno Therapeutics?
Juno Therapeutics has a market capitalization of $9.93 billion and generates $111.87 million in revenue each year. Juno Therapeutics employs 553 workers across the globe.
How can I contact Juno Therapeutics?
Juno Therapeutics' mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The biopharmaceutical company can be reached via phone at +1-206-5821600.
MarketBeat Community Rating for Juno Therapeutics (NASDAQ JUNO)
MarketBeat's community ratings are surveys of what our community members think about Juno Therapeutics and other stocks. Vote "Outperform" if you believe JUNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JUNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
